comprehensive -WSS

comprehensive

author：leisure time 2025-09-27 16:49:40 - browse：78

Jamy Ard (left) and Robert Lustig (right) on the 2023 STAT Breakthrough Summit stage -- coverage from STAT — Obesity experts Jamy Ard (left) and Robert Lustig speak at a panel during the 2023 STAT Breakthrough Summit. Sarah Gonzalez for STAT

Amid rising demand for drugs like Wegovy, Ozempic, and Mounjaro that can lead to significant weight loss, some obesity experts are concerned about the drugs’ costs — both to patients’ finances and to their health.

Speaking at a panel on new obesity treatments at the STAT Breakthrough Summit in San Francisco on Thursday, one expert cited a large clinical trial for Wegovy that showed that about 40% of the weight participants lost was lean mass. Side effects like nausea, vomiting, and a possible link to rare cases of pancreatitis also still plague this newest class of drugs, which imitate the effects of a hormone called glucagon-like peptide 1 (GLP) that helps people feel full.

“That’s what starvation does. You lose equal amounts of muscle and fat,” said Robert Lustig, emeritus professor of pediatrics at the University of California, San Francisco. “If you’re a person 60 years old or over and you’re losing muscle, your risk of dying just went up exponentially. So we may be … robbing Peter to pay Paul.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Ultragenyx gene therapy for rare liver ailment succeeds in late

hotspot

WSS

In 'major milestone,' FDA approves first cell therapy for solid tumors

Researchers tackle phage therapy hurdles for wider adoption

Medicare Advantage enrollment hits roughly 33.4 million

The Pandemic Treaty must support building strong health systems

ASCO: Palliative care found as helpful given virtually as in person

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

explore

comprehensive

focus

Trump demands the U.S. pay no more for drugs than other countries … again

The Pandemic Treaty must support building strong health systems

New air purifier tech could be key to improving indoor air quality

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

How to save PrEP access — and even expand it

Abridge raises $150m as clinical notes automation market heats up

Hepatitis C has a cure — but many Americans still lack access to it

Researchers tackle phage therapy hurdles for wider adoption

FDA approval of Sarepta Duchenne genetic therapy gives me hope

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

explore

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Congress may force more Covid

Secretariat’s lessons for human medicine

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

The Pandemic Treaty must support building strong health systems

explore

hotspot

hotspot

knowledge